Latest New Zealand News

A New Zealand community group has filed a court application to halt the Toi Foundation trustees from voting on the sale of TSB Bank to Heartland, potentially complicating the merger timeline.

Kingfish Limited posted a net loss of NZD 13.6 million for FY2026, underperforming the NZX50 benchmark, but showed early signs of recovery in FY2027. The company re-elected two directors and maintained its focus on quality growth stocks amid a cautious economic outlook.

AVITA Medical posted robust Q2 2026 results with 18% revenue growth, driven by RECELL and supported by Cohealyx and PermeaDerm, and now expects to reach cash flow breakeven by year-end.

Nick Scali Limited posted a 31% jump in net profit after tax to $75.7 million for FY26, driven by margin gains and UK sales recovery, and announced a fully franked final dividend of 39 cents per share.

James Hardie Industries posted a 64% jump in Q1 FY27 net sales to $1.475 billion, powered by the AZEK acquisition and solid organic growth. The company exceeded EBITDA guidance and raised its full-year outlook, targeting robust sales and cash flow growth amid cautious housing market assumptions.

NZME has agreed to acquire Stuff’s Petone print plant equipment, aiming to cut operating costs and right size its production capacity. The move involves up to $15 million in investment with expected annual savings of around $7 million once operational.

Asset Plus Limited (NZX:APL) has increased its third quarter dividend to 0.25 cents per share, up from 0.20 cents, reflecting stronger Funds from Operations driven by a new lease at Munroe Lane.

ReNerve has secured marketing approval for its NervAlign® Nerve Cuff in the Philippines, tapping into a major Southeast Asian market with significant nerve injury demand.

Hawsons Iron (ASX:HIO) is aiming to raise up to A$1.5 million through a discounted Share Purchase Plan, sweetened with free attaching unlisted options exercisable at A$0.015 each.

Dimerix CEO Dr Nina Webster detailed the company’s geographic and product diversification at the Bioshares Summit, spotlighting the commercial potential of DMX-200 and the newly acquired Phase 2 asset DMX-652 targeting acute kidney injury.

Kinatico Limited reports a robust FY26 with SaaS revenue growth driving total revenue up 9.4% to $35.2 million and net profit after tax soaring 78.5% to $2.0 million, underpinned by its AI-native compliance platform.

New Zealand King Salmon (NZX: NZK) has upgraded its FY26 earnings outlook, lifting pro-forma EBITDA guidance to $30 million–$34 million, driven by better fish performance and fewer supply chain disruptions than expected.